New cancer drug seeks right dose to fight tough tumors
NCT ID NCT06939283
Summary
This early-stage trial is testing a new drug called WTX-330 in adults with advanced solid tumors or non-Hodgkin lymphoma that have stopped responding to standard treatments. The main goals are to find the safest and most effective dose and to see if the drug can shrink tumors. Researchers will also study how the drug works in the body and its effects on the immune system.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.